Dataset Information

A systems approach reveals SMARCD3 regulon drives alternate growth signaling and vulnerability to MEK inhibitors in everolimus resistant breast cancer cells

ABSTRACT: Estrogen receptor-positive breast cancer (ER+BC) represents nearly 75% of all breast tumors, with nearly 20-40% patients eventually developing metastases. Everolimus is an mTOR inhibitor which has been approved for use in combination with exemestane in patients with metastatic ER+BC. However, many patients eventually develop resistance to everolimus leading to poor survival outcomes. Systematic characterization of the molecular phenotypes underlying everolimus resistance could reveal new therapeutic targets for metastatic ER+BC. We analyzed transcriptomic profiles from multiple pairs of everolimus resistant or sensitive ER+BC cell lines, to identify signaling mechanisms that distinguish resistant cells both at baseline and under everolimus treatment. Using a linear mixed-effects model, we identified strong activation of the growth-factor signaling meta-phenotype in resistant cells at baseline, which persisted even under everolimus treatment. This meta phenotype included alternate growth signaling mechanisms including IGF1R/insulin, ESR1, RAS and MAPK signaling. To understand the regulatory mechanism behind alternate growth-factor signaling activation, we adopted a network reconstruction architecture to identify SMARCD3 regulons as key transcriptional regulatory networks in resistant cells. In a neo-adjuvant trial for ER+BC patients, the expression levels of SMARCD3 and its regulon’s activity were significantly elevated in tumors refractory to everolimus. To develop a therapeutic strategy against everolimus resistance, we used transcriptomic and drug sensitivity profiles of 926 cancer cell lines treated with 395 compounds. We found that the activation of SMARCD3 regulons was consistently associated with sensitivity to several known MEK1/2 inhibitors, including trametinib. To validate these findings, we evaluated the efficacy of everolimus in combination with trametinib and demonstrated that the combination treatment significantly reduced the growth of resistant cells compared to everolimus. Our results demonstrate that everolimus resistant ER+BC cells utilize alternate growth-factor signaling to escape therapeutic control. We found that this phenotype is strongly linked with activation of the SMARCD3 regulons and can be therapeutically targeted using MEK1/2 inhibitors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE286174 | GEO | 2025/12/11

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other
	GSE286174_COH069_15929R_everSamples_data.counts.txt.gz	Txt
	GSE286174_COH069_15929R_everSamples_data.tpm.txt.gz	Txt

Items per page:

1 - 3 of 3

Similar Datasets

Project description:Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, to date, key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. Mechanistically, H-FOXA1 reprograms ER-chromatin binding to elicit a core gene signature (CGS) highly enriched in ER+ endocrine-resistant (EndoR) cells. We identified Secretome14, a CGS subset encoding ER-dependent cancer secretory proteins, strongly predicts poor outcomes of ER+ BC and is elevated in ER+ metastases vs. primary tumors, irrespective to the ESR1 mutations. Parental (P) ER+ BC cells and their endocrine-resistant (EndoR) derivatives, and ER+ BC cells expressing doxycycline (Dox)-inducible ectopic FOXA1 were used in this study. Differential gene expression analysis was performed in EndoR vs. P cells and P cells +Dox vs. -Dox. We found that the FOXA1-CGS was highly enriched in the altered transcriptomes of two ER+ BC cell models (ZR75-1 and T47D) expressing ectopic H-FOXA1. The enriched hallmark gene sets, shared by the H-FOXA1 cell models, include “inflammatory response”, “complement”, and “interferon gamma response” for the H-FOXA1-induced, and “estrogen response early” and “estrogen response late” for the H-FOXA1-repressed genes. These findings point to the common transcriptional profile exhibiting an immune- over estrogen-responsive signature induced by H-FOXA1. In addition, we found that both the tamoxifen-resistant (TamR) and estrogen deprivation-resistant (EDR) derivatives of the 600MPE P cells were enriched for the H-FOXA1-induced CGS and FOXA1/ER-activated Secretome14. Our findings uncover H-FOXA1-induced ER reprogramming driving EndoR and metastasis, possibly via a H-FOXA1/ER-dependent secretome that warrants further studies to clarify its involvement in disease progression of ER+ metastatic BC.

Project description:Estrogen receptor α (ER-α) is a major driver of breast cancer (BC), being expressed in 75% of all BC cases. Agents such as tamoxifen are used to block ER-α activity and interfere with its down-stream oncogenic singling. However, a major problem associated with tamoxifen is the emergence of resistance. Resistant BC is often associated with aggressive relapse, metastasis, and high mortality rates of 80%. A key mechanism for development of resistance is activation of EGFR/HER2/HER3 signaling pathways and other hormone receptors (androgen receptor (AR), progesterone receptor (PR), prolactin receptors (PRL-R)) that can intrinsically activate ER-α. This study investigated a novel class of thiosemicarbazone anti-cancer agents, namely Dp44mT and DpC, on the expression and activation between major BC hormonal receptors, their co-factors and key pathways involved in resistance in ER-α-positive BC using RNA sequencing, immunoblotting and confocal microscopy and an in vivo orthotopic BC model. For the first time, we demonstrate that DpC and Dp44mT markedly reduce the expression of ER-α, AR, PR and PRL-R by inducing their proteasomal degradation. Further, these agents also inhibited EGFR, HER2 and HER3 activation in ER-α-positive BC cells, suggesting their potential ability to overcome development of resistance. Importantly, expression of key co-factors that promote ER-α-transcriptional activity, including SRC3, c-Myc, SP1, and c-Src, were also decreased by these agents. This study demonstrates for the first time the multi-axial inhibitory effects of the novel DpT agents in ER-positive BC invitro and in vivo. We demonstrate that Dp44mT and DpC decrease ER-α expression, transcriptional activity, and promote its proteasomal degradation. This study also demonstrated the ability of the DpT agents in inhibiting RTKs and key oncogenic pathways that are well established to promote endocrine resistance. Hence, for the first time we demonstrate that Dp44mT and DpC may be a promising therapeutic approach to treat ER-positive BC and to overcome resistance to conventional BC therapies.

Dataset Information

A systems approach reveals SMARCD3 regulon drives alternate growth signaling and vulnerability to MEK inhibitors in everolimus resistant breast cancer cells

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets